Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation?
Park
S-J
SJ
Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Paik
S W
SW
Choi
M S
MS
Lee
J H
JH
Koh
K C
KC
Kim
S J
SJ
Joh
J W
JW
Lee
S K
SK
D000328:Adult; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D007136:Immunoglobulins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin